• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » EnteroMedics touts 18-month sham-controlled data on vBloc device

EnteroMedics touts 18-month sham-controlled data on vBloc device

July 16, 2015 By Fink Densford

Enteromedics touts 18-month sham-controlled data on vBloc deviceEnteroMedics (NSDQ:ETRM) said today that 18-month results of a sham-controlled study of its vBloc therapy, used by its flagship Maestro device, was published in the Journal of Obesity

The 239-patient pivotal Recharge trial examined weight-loss differences between patients who were implanted with the Maestro device, which provides vBloc therapy, and patients who were implanted with a similar neuroregulator that did not.

At 12 months, patients treated with vBloc therapy demonstrated 25.8% excess weight loss, 8.9% greater than the excess weight loss achieved by patients in the sham group. At 18 months, vBloc patients sustained 23.5% excess weightloss, versus 10.2% in the sham group.

“Because of the cyclical nature of obesity, sustainable weight loss is a critical measure of success in the treatment of this disease. Results at 18 months from the ReCharge Study demonstrate both the sustainability of weight loss using vBloc Therapy, a distinct contrast to the weight regain experienced by the sham control group, and the unique safety profile of the device over time. Publication of these results underscores vBloc Therapy’s important new position within the obesity treatment spectrum, where, historically, options such as anatomy altering or restricting surgery have required substantial tradeoffs in lifestyle, nutrition and safety,”  lead author and EnteroMedics chief medical officer Dr. Scott Shikora said in a press release.

The Maestro device functions by stimulating the vagal nerve, which is associated with hunger and satiety, in a specific manner that St. Paul, Minn.-based Enteromedics says helps patients lose weight. To control for differences between groups, the sham devices contained a similar neuroregulator that dissipated charge into a resistor at a rate similar to the active device.

The study will continue to track patients up to 5-years. Additional long-term data and continued follow-up data are needed to further evaluate the safety and effectiveness of vBloc therapy, according to the study.

Earlier this month, Enteromedics closed a $14.7 million follow-on offering it initially hoped would gross $35 million. The company initially planned to float 40.2 million shares at 87¢ apiece,for gross proceeds of $35 million. That offering was to have consisted of 1 ETRM share, plus Series A and Series B warrants. But the company was forced to cancel the issue after the NASDAQ Capital Market said wouldn’t approved the transaction.

Instead, EnteroMedics retooled the offering to 32 million shares at 50¢ apiece, comprised of 1 ETRM share plus Series A warrants.

Filed Under: Clinical Trials, Implants, Weight loss Tagged With: EnteroMedics Inc.

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy